Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.60 USD
Change Today 0.00 / 0.00%
Volume 0.0
ARNI On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 04/16/15 All times are local (Market data is delayed by at least 15 minutes).

arno therapeutics inc (ARNI) Snapshot

Open
$0.60
Previous Close
$0.60
Day High
$0.60
Day Low
$0.60
52 Week High
04/21/14 - $2.20
52 Week Low
12/16/14 - $0.43
Market Cap
12.2M
Average Volume 10 Days
3.2K
EPS TTM
$0.31
Shares Outstanding
20.4M
EX-Date
--
P/E TM
1.9x
Dividend
--
Dividend Yield
--
Current Stock Chart for ARNO THERAPEUTICS INC (ARNI)

Related News

No related news articles were found.

arno therapeutics inc (ARNI) Related Businessweek News

No Related Businessweek News Found

arno therapeutics inc (ARNI) Details

Arno Therapeutics, Inc., a development stage company, focuses on developing products for the treatment of cancer. Its product development pipeline includes Onapristone, a type 1 anti-progestin hormone blocker, which is in Phase I dose escalation clinical trial in post-menopausal women for the treatment of breast, endometrial, and others solid tumors; and Phase I/II clinical trial in men for the treatment of advanced castration-resistant prostate cancer. The company also develops AR-42, an orally available spectrum inhibitor of histone and non-histone deacetylation proteins that is in Phase I/IIa clinical study for the treatment of hematological malignancies and solid tumors; and AR-12, an orally available targeted anti-cancer agent, which has completed Phase I clinical study for the treatment of solid tumors and hematological malignancies. It has a collaboration and licensing agreement with Leica Biosystems Newcastle Ltd. for developing a companion diagnostic for Onapristone; and licensing agreement with Invivis Pharmaceuticals, Inc. Arno Therapeutics, Inc. is based in Flemington, New Jersey.

7 Employees
Last Reported Date: 03/31/15

arno therapeutics inc (ARNI) Top Compensated Officers

Chief Executive Officer, Chief Medical Office...
Total Annual Compensation: $591.6K
Chief Development Officer
Total Annual Compensation: $311.8K
Compensation as of Fiscal Year 2013.

arno therapeutics inc (ARNI) Key Developments

Arno Therapeutics, Inc. Announces Consolidated Unaudited Financial Results for the Fourth Quarter and Full Year Ended December 31, 2014

Arno Therapeutics, Inc. announced consolidated unaudited financial results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported loss from operations of $3,891,000 against $5,899,000 a year ago. Net income was $4,563,000 against net loss of $23,739,000 a year ago. Net income per diluted share was $0.18 against net loss per diluted share of $1.51 a year ago. Adjusted net loss (non-GAAP) was $2,830,000 against $5,366,000 a year ago. Adjusted net loss per basic share was $0.14 against $0.34 a year ago. The primary factor for the $2.5 million year-over-year improvement in adjusted (non-GAAP) net loss compared to the fourth quarter of 2013 was reduced spending on non-clinical research and CMC activities in 2014 totaling $2.1 million. For the full year, the company reported loss from operations of $21,493,000 against $16,941,000 a year ago. Net income was $7,771,000 against net loss of $39,657,000 a year ago. Net income per diluted share was $0.31 against net loss per diluted share of $5.28 a year ago. Adjusted net loss (non-GAAP) was $16,898,000 against $15,037,000 a year ago. Adjusted net loss per basic share was $0.83 against $2.01 a year ago. The $1.9 million increase in adjusted (non-GAAP) net loss for the full year 2014, was due to increased R&D expenses, primarily associated with the initiation in 2014 of the two phase I/II clinical trials for onapristone.

Arno Therapeutics, Inc. Presents at Noble Financial Capital Markets Eleventh Annual Investor Conference, Jan-20-2015 04:00 PM

Arno Therapeutics, Inc. Presents at Noble Financial Capital Markets Eleventh Annual Investor Conference, Jan-20-2015 04:00 PM. Venue: Club Med, Sandpiper Bay, Florida, United States. Speakers: Lawrence A. Kenyon, Chief Financial Officer, Chief Operating Officer and Principal Accounting Officer.

Arno Therapeutics to Present Data Further Validating Diagnostic Development of CDx for Onapristone at San Antonio Breast Cancer Symposium 2014

Arno Therapeutics, Inc. announced that data from a study supporting diagnostic development for its lead compound onapristone will be presented at a poster session at the 2014 San Antonio Breast Cancer Symposium (SABCS), being held December 9-13, 2014 in San Antonio, Texas. The study evaluated the impact of using a progesterone receptor (PR) isotype-specific immunohistochemical (IHC) diagnostic technique on the diagnosis of triple-negative breast cancer tumors, which are defined as estrogen receptor (ERα), PR and HER2 negative. PR cellular expression is thought to be linked to ERα expression in breast cancer. Triple-negative breast cancer may express PR when tested with two forms of the PR: PRA and PRB antibodies. Routine IHC determination of PR utilizes "bispecific" antibodies which recognize epitopes common to both PRA and PRB. Ultimately, the accuracy of triple-negative phenotype determination depends in part on the ability of the antibody to detect both PRA and PRB expression in the tumor. The study evaluated 775 archived breast cancer tumor samples from female patients diagnosed with invasive ductal breast cancer provided by Oscar Lambret Hospital in Lille, France. The samples were analyzed for ERα, PRA and PRB. Of the samples, 89 cases were determined to be ERα negative (by retesting) and HER2 negative (from patient records). Evaluating the PR status with IHC staining demonstrated that 53 of the 89 cases (60%) were found to be 'true' triple negative using isotype specific antibodies for PRA and PRB. Furthermore, results showed that 21 of the 89 (24%) were PR positive using the PRA and PRB antibodies tested and 15 of the 89 (17%) were found to be PR positive with either the PRA or PRB antibody and not with the PR bispecific antibody used in standard PR testing. The use of PRA and PRB isotype-specific antibodies may reveal breast cancer cases that are not necessarily triple negative.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ARNI:US $0.60 USD 0.00

ARNI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ARNI.
View Industry Companies
 

Industry Analysis

ARNI

Industry Average

Valuation ARNI Industry Range
Price/Earnings 1.9x
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow 1.6x
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARNO THERAPEUTICS INC, please visit www.arnothera.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.